title: Outcomes of allogenic acellular matrix therapy in treatment of diabetic foot wounds: an initial experience.
abstract: The purpose of this study was to evaluate outcomes of persons with UT grade 2A neuropathic diabetic foot wounds treated with an acellular matrix. Data were abstracted for 17 consecutive patients with diabetes--76.5% males, aged 61.5 +/- 8.5 years with a mean glycated haemoglobin of 9.2 +/- 2.2% presenting for care at a large, multidisciplinary wound care centre. All patients received surgical debridement for their diabetic foot wounds and were placed on therapy consisting of a single application of an acellular matrix graft (GraftJacket; Wright Medical Technologies, Arlington, TN, USA) with dressing changes taking place weekly. Outcomes evaluated included time to complete wound closure and proportion of patients achieving wound closure in 20 weeks. Acellular matrix therapy was used as initial therapy and was sutured or stapled in place under a silicone-based non adherent dressing. Therapy was then followed by a moisture-retentive dressing until complete epithelialisation. In total, 82.4% of wounds measuring a mean 4.6 +/- 3.2 cm(2) healed in the 20-week evaluation period. For those that healed in this period, healing took place in a mean 8.9 +/- 2.7 weeks. We conclude that a regimen consisting of moist wound healing using an acellular matrix dressing may be a useful adjunct to appropriate diabetic foot ulcer care for deep, non-infected, non-ischaemic wounds. We await the completion of further trials in this area to confirm or refute this initial assessment.
authors.affiliation: Department of Surgery, Southern Arizona Veterans Affairs Medical Center, Tucson, AZ, USA.
authors.forename: Billy R
authors.initials: BR
authors.lastname: Martin
authors.forename: Melinda
authors.initials: M
authors.lastname: Sangalang
authors.forename: Stephanie
authors.initials: S
authors.lastname: Wu
authors.forename: David G
authors.initials: DG
authors.lastname: Armstrong
mesh_terms: D000368:Aged; D001684:Biological Dressings; D003646:Debridement; D020405:Dermis / Q000637:transplantation*; D017719:Diabetic Foot / Q000473:pathology / Q000628:therapy*; D016326:Extracellular Matrix Proteins / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013997:Time Factors; D023822:Tissue Engineering; D016896:Treatment Outcome
chemical_list: D016326:Extracellular Matrix Proteins